Bridgebio Pharma Stock Total Debt
| BBIO Stock | USD 31.40 0.17 0.54% |
BridgeBio Pharma fundamentals help investors to digest information that contributes to BridgeBio Pharma's financial success or failures. It also enables traders to predict the movement of BridgeBio Stock. The fundamental analysis module provides a way to measure BridgeBio Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BridgeBio Pharma stock.
As of the 10th of March 2025, Total Debt To Capitalization is likely to grow to -0.006.
BridgeBio | Total Debt |
BridgeBio Pharma Company Total Debt Analysis
BridgeBio Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current BridgeBio Pharma Total Debt | 9.2 M |
Most of BridgeBio Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BridgeBio Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BridgeBio Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for BridgeBio Pharma is extremely important. It helps to project a fair market value of BridgeBio Stock properly, considering its historical fundamentals such as Total Debt. Since BridgeBio Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BridgeBio Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BridgeBio Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
BridgeBio Total Debt Historical Pattern
Today, most investors in BridgeBio Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BridgeBio Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BridgeBio Pharma total debt as a starting point in their analysis.
BridgeBio Pharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
BridgeBio Net Debt
Based on the latest financial disclosure, BridgeBio Pharma has a Total Debt of 9.2 M. This is 99.67% lower than that of the Biotechnology sector and 97.17% lower than that of the Health Care industry. The total debt for all United States stocks is 99.83% higher than that of the company.
BridgeBio Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BridgeBio Pharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BridgeBio Pharma could also be used in its relative valuation, which is a method of valuing BridgeBio Pharma by comparing valuation metrics of similar companies.BridgeBio Pharma is currently under evaluation in total debt category among its peers.
BridgeBio Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of BridgeBio Pharma from analyzing BridgeBio Pharma's financial statements. These drivers represent accounts that assess BridgeBio Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BridgeBio Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 8.4B | 2.4B | 1.1B | 6.6B | 5.1B | 3.2B | |
| Enterprise Value | 8.5B | 3.7B | 2.5B | 7.9B | 4.4B | 3.5B |
BridgeBio Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BridgeBio Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Pharma's managers, analysts, and investors.Environmental | Governance | Social |
BridgeBio Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in BridgeBio Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BridgeBio Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BridgeBio Pharma's value.| Shares | |||
| Alliancebernstein L.p. | 2024-12-31 | 2.8 M | |
| Woodline Partners Lp | 2024-12-31 | 2.2 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2 M | |
| Ensign Peak Advisors Inc | 2024-12-31 | 2 M | |
| Manufacturers Life Insurance Co | 2024-12-31 | 1.9 M | |
| Sc Us (ttgp), Ltd. | 2024-12-31 | 1.9 M | |
| Ubs Group Ag | 2024-12-31 | 1.8 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 1.8 M | |
| Fmr Inc | 2024-12-31 | 1.6 M | |
| Kohlberg Kravis Roberts & Co Lp | 2024-12-31 | 25.3 M | |
| Viking Global Investors Lp | 2024-12-31 | 25.1 M |
BridgeBio Fundamentals
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.48 | ||||
| Profit Margin | (2.41) % | ||||
| Operating Margin | (37.63) % | ||||
| Current Valuation | 7.05 B | ||||
| Shares Outstanding | 190.19 M | ||||
| Shares Owned By Insiders | 5.42 % | ||||
| Shares Owned By Institutions | 94.34 % | ||||
| Number Of Shares Shorted | 20.18 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 27.06 X | ||||
| Revenue | 221.9 M | ||||
| Gross Profit | 218.02 M | ||||
| EBITDA | (436.83 M) | ||||
| Net Income | (543.35 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 9.2 M | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (7.72) X | ||||
| Cash Flow From Operations | (520.73 M) | ||||
| Short Ratio | 7.43 X | ||||
| Earnings Per Share | (2.88) X | ||||
| Price To Earnings To Growth | 0.05 X | ||||
| Target Price | 53.56 | ||||
| Number Of Employees | 725 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 6 B | ||||
| Total Asset | 919.34 M | ||||
| Retained Earnings | (3.1 B) | ||||
| Working Capital | 566.29 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
| Net Asset | 919.34 M |
About BridgeBio Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BridgeBio Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BridgeBio Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BridgeBio Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock: Check out BridgeBio Pharma Piotroski F Score and BridgeBio Pharma Altman Z Score analysis. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.